FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045464562> ?p ?o ?g. }

• W3045464562 abstract "Objective. To investigate predictors of patient-reported urinary incontinence (PRUI) in the first 2 years after post-prostatectomy radiotherapy (PORT) with particular emphasis on possible dose-effect relationships. Patients and Methods. Two-hundred-thirteen patients, whose clinical and dosimetric data were prospectively collected within a registered multi-institutional cohort study, underwent PORT with adjuvant (n=106) or salvage (n=107) intent with conventional (n=123, prescribed dose to the prostatic bed: 66.6-79.8Gy in 1.8-2.0Gy/fr) or moderately hypo- (n=90, 65.8-76.8Gy in 2.1-2.7Gy/fr) fractionation during the period 2011-2017. PRUI was evaluated through the ICIQ-SF questionnaire filled in at baseline and every six months thereafter. The analysis focused on three ICIQ-based clinically relevant endpoints: (a) very frequent leakage (FREQUENCY, ICIQ3 score >3), (b) moderate to severe amount of urine loss (AMOUNT, ICIQ4>2) (c) objective severe symptoms (OBJECTIVE, ICIQ3+4>5). Predictors of the incidence within 2 years for the three endpoints were investigated focusing only on patients without endpoint symptoms at baseline. A uni-variable logistic regression analysis was performed in order to determine the best dose metrics describing PRUI risk in terms of 2-Gy equivalent dose (EQD2) calculated with different α⁄β values reported in the literature (0.8, 3, 5Gy), and to identify the most significant clinical variables. Variables showing p<0.20 at uni-variable analysis were entered into a backward stepwise multi-variable logistic regression analysis. Lastly, the goodness of fit and model calibration were evaluated and internally validated. Results. Patients without symptoms at baseline experienced (a), (b) and/or (c) within 2 years in 41/130 (32%), 40/192 (21%) and 41/129 (32%) of the cases, respectively. EQD2 for α⁄β=0.8Gy was the best dose metric associated with PRUI. Multi-variable analysis identified baseline incontinence levels as the strongest predictor for all endpoints (p<0.006). Both FREQUENCY and OBJECTIVE were significantly influenced also by EQD2(α⁄β=0.8Gy). The goodness of fit was excellent, as was the calibration; internal calibration confirmed apparent performance. Conclusion. Baseline mild urinary incontinence symptoms strongly modulate the 2-year risk of PRUI. In addition, FREQUENCY is characterized by a marked dose-effect relationship also influencing the trend of OBJECTIVE, with results more reliable than AMOUNT as an objective index. A strong impact of fractionation on severe PRUI after post-prostatectomy radiotherapy also emerged." @default.
• W3045464562 created "2020-07-29" @default.
• W3045464562 creator A5002383005 @default.
• W3045464562 creator A5004091943 @default.
• W3045464562 creator A5004740394 @default.
• W3045464562 creator A5005703886 @default.
• W3045464562 creator A5008462348 @default.
• W3045464562 creator A5011697206 @default.
• W3045464562 creator A5018063898 @default.
• W3045464562 creator A5019947661 @default.
• W3045464562 creator A5027049576 @default.
• W3045464562 creator A5035610805 @default.
• W3045464562 creator A5035741802 @default.
• W3045464562 creator A5039609795 @default.
• W3045464562 creator A5045843939 @default.
• W3045464562 creator A5045871192 @default.
• W3045464562 creator A5048161006 @default.
• W3045464562 creator A5051193104 @default.
• W3045464562 creator A5058751447 @default.
• W3045464562 creator A5060926690 @default.
• W3045464562 creator A5077224068 @default.
• W3045464562 creator A5077550825 @default.
• W3045464562 date "2020-07-23" @default.
• W3045464562 modified "2023-10-07" @default.
• W3045464562 title "Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects" @default.
• W3045464562 cites W1983428801 @default.
• W3045464562 cites W1998201907 @default.
• W3045464562 cites W1998994702 @default.
• W3045464562 cites W2001409689 @default.
• W3045464562 cites W2026417356 @default.
• W3045464562 cites W2053690746 @default.
• W3045464562 cites W2060139124 @default.
• W3045464562 cites W2074840514 @default.
• W3045464562 cites W2077786236 @default.
• W3045464562 cites W2116691961 @default.
• W3045464562 cites W2126763861 @default.
• W3045464562 cites W2148117492 @default.
• W3045464562 cites W2208191807 @default.
• W3045464562 cites W2304767321 @default.
• W3045464562 cites W2312982074 @default.
• W3045464562 cites W2344379077 @default.
• W3045464562 cites W2431449819 @default.
• W3045464562 cites W2552100324 @default.
• W3045464562 cites W2587500057 @default.
• W3045464562 cites W2612542171 @default.
• W3045464562 cites W2738546473 @default.
• W3045464562 cites W2750158116 @default.
• W3045464562 cites W2753531805 @default.
• W3045464562 cites W2766039492 @default.
• W3045464562 cites W2988378549 @default.
• W3045464562 cites W2993539218 @default.
• W3045464562 doi "https://doi.org/10.3389/fonc.2020.01207" @default.
• W3045464562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7396712" @default.
• W3045464562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32850354" @default.
• W3045464562 hasPublicationYear "2020" @default.
• W3045464562 type Work @default.
• W3045464562 sameAs 3045464562 @default.
• W3045464562 citedByCount "5" @default.
• W3045464562 countsByYear W30454645622021 @default.
• W3045464562 countsByYear W30454645622023 @default.
• W3045464562 crossrefType "journal-article" @default.
• W3045464562 hasAuthorship W3045464562A5002383005 @default.
• W3045464562 hasAuthorship W3045464562A5004091943 @default.
• W3045464562 hasAuthorship W3045464562A5004740394 @default.
• W3045464562 hasAuthorship W3045464562A5005703886 @default.
• W3045464562 hasAuthorship W3045464562A5008462348 @default.
• W3045464562 hasAuthorship W3045464562A5011697206 @default.
• W3045464562 hasAuthorship W3045464562A5018063898 @default.
• W3045464562 hasAuthorship W3045464562A5019947661 @default.
• W3045464562 hasAuthorship W3045464562A5027049576 @default.
• W3045464562 hasAuthorship W3045464562A5035610805 @default.
• W3045464562 hasAuthorship W3045464562A5035741802 @default.
• W3045464562 hasAuthorship W3045464562A5039609795 @default.
• W3045464562 hasAuthorship W3045464562A5045843939 @default.
• W3045464562 hasAuthorship W3045464562A5045871192 @default.
• W3045464562 hasAuthorship W3045464562A5048161006 @default.
• W3045464562 hasAuthorship W3045464562A5051193104 @default.
• W3045464562 hasAuthorship W3045464562A5058751447 @default.
• W3045464562 hasAuthorship W3045464562A5060926690 @default.
• W3045464562 hasAuthorship W3045464562A5077224068 @default.
• W3045464562 hasAuthorship W3045464562A5077550825 @default.
• W3045464562 hasBestOaLocation W30454645621 @default.
• W3045464562 hasConcept C120665830 @default.
• W3045464562 hasConcept C121332964 @default.
• W3045464562 hasConcept C121608353 @default.
• W3045464562 hasConcept C126322002 @default.
• W3045464562 hasConcept C126894567 @default.
• W3045464562 hasConcept C141071460 @default.
• W3045464562 hasConcept C151956035 @default.
• W3045464562 hasConcept C203092338 @default.
• W3045464562 hasConcept C2778531004 @default.
• W3045464562 hasConcept C2779466945 @default.
• W3045464562 hasConcept C2780192828 @default.
• W3045464562 hasConcept C509974204 @default.
• W3045464562 hasConcept C535046627 @default.
• W3045464562 hasConcept C61511704 @default.
• W3045464562 hasConcept C71924100 @default.
• W3045464562 hasConcept C72563966 @default.
• W3045464562 hasConceptScore W3045464562C120665830 @default.
• W3045464562 hasConceptScore W3045464562C121332964 @default.

• next